Efficacy of Early Combination Therapy With Lianhuaqingwen and Arbidol in Moderate and Severe COVID-19 Patients: A Retrospective Cohort Study
ObjectiveSince the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan City, China, coronavirus disease 2019 (COVID-19) has become a global pandemic. However, no special therapeutic drugs have been identified for COVID-19. The aim of this study was to search for drugs t...
Saved in:
Main Authors: | Jie Fang (Author), Hui Li (Author), Wei Du (Author), Ping Yu (Author), Ying-Yun Guan (Author), Shi-Yu Ma (Author), Dong Liu (Author), Wei Chen (Author), Guo-Chao Shi (Author), Xiao-Lan Bian (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2020-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effectiveness of Arbidol for COVID-19 Prevention in Health Professionals
by: Chunguang Yang, et al.
Published: (2020) -
Protective Effect of Arbidol Against Pulmonary Fibrosis and Sepsis in Mice
by: Hailong Li, et al.
Published: (2021) -
Inhibitory effect of napabucasin on arbidol metabolism and its mechanism research
by: Jingjing Nie, et al.
Published: (2023) -
A retrospective study of Pupingqinghua prescription versus Lianhuaqingwen in Chinese participants infected with SARS-CoV-2 Omicron variants
by: Yidan Dong, et al.
Published: (2022) -
Preparation and evaluation of taste masked oral suspension of arbidol hydrochloride
by: Ling Wang, et al.
Published: (2015)